GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders. Its route of administration is unspecified.
The drug is a highly potent agonist of the human KOR, with an affinity (Ki) of 0.9nM or 87.3nM depending on the radioligand and an of 0.8nM. In contrast to noribogaine, it did not show pro-arrhythmic effects in fresh human ventricular cardiomyocytes ex vivo. GM-3009 produces antinociceptive effects and dose-dependently reduces oxycodone self-administration in rodents.
It is being developed by Gilgamesh Pharmaceuticals. As of June 2024, it is in the preclinical research stage of development. The exact chemical structure of GM-3009 does not yet appear to have been disclosed. However, it is known to be an "oxa-iboga" derivative. Oxa-ibogaine analogues have notably been patented and studied by Dalibor Sames and colleagues, with Sames being a co-founder of Gilgamesh Pharmaceuticals.
See also κ-Opioid receptor agonist List of investigational hallucinogens and entactogens Oxa-noribogaine 4-Allyl-6-oxa-noribogainalog
References